Hudson Technologies (Nasdaq: HDSN) $4.05. Announced Wednesday after market close results for the first quarter ended March 31, 2013. Revenues for the three months ended March 31, 2013 increased by 54% to $22,877,000 from $14,854,000 in the comparable 2012 period. Net income for the first quarter was $4,469,000, or $0.18 per basic share and $0.17 per diluted share, compared to net income of $2,509,000, or $0.11 per basic share and $0.10 per diluted share for the first quarter of 2012.
What They Do: Hudson Technologies, Inc. is a leading provider of innovative solutions to recurring problems within the refrigeration industry.
Mattson Technology ( Nasdaq : MTSN ) $1.44. Announced Wednesday after market close results for the first quarter ended March 31, 2013. First quarter 2013 net sales of $20.2 million, essentially flat as compared to net sales of $20.7 million in the fourth quarter of 2012, but a decrease of $30.3 million, or 60 percent, compared to net sales $50.5 million in the first quarter of 2012.
Net loss for the first quarter of 2013 was $9.5 million, or a $0.16 net loss per share. This compares to a net loss of $8.8 million, or a $0.15 net loss per share, in the fourth quarter of 2012, and a net loss of $1.1 million, or a $0.02 net loss per share, reported in the first quarter of 2012. Excluding restructuring and other charges, the non-GAAP net loss per share in the first quarter of 2013 was $0.12 as compared to a non-GAAP net loss per share of $0.10 in the fourth quarter of 2012 and a non-GAAP net loss per share of $0.01 in the fourth quarter of 2012. Restructuring and other charges in the first quarter of 2013, fourth quarter of 2012, and first quarter of 2012 were $2.3 million, $3.1 million, and $0.7 million, respectively.
What They Do: Mattson Technology, Inc. designs, manufactures and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits.
Palatin Technologies (NYSE: PTN) $0.63. Today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 12/952,238 (the '238 application). The application includes composition of matter claims on a new class of melanocortin receptor- specific peptides for sexual dysfunction and other indications.
The '238 application is the first patent application to issue covering a novel family of melanocortin-4 receptor agonist peptides. The melanocortin-4 receptor mediates sexual response, and agonists have been studied for treatment of both erectile dysfunction and female sexual dysfunction. Palatin's bremelanotide product, a melanocortin-4 receptor agonist peptide drug administered using an autoinjector, has recently completed Phase 2 human studies for female sexual dysfunction, with pivotal Phase 3 clinical studies scheduled to start later this year.
What They Do: Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.